Iain Stuart, PhD: VYN202 Positive Safety and Tolerability in Phase 1a
VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease
Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.
VYN201 for Vitiligo: Promising Data Showcases Potential of BET Inhibition
VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.
Day 2 Recap: AAD 2025
Late-Breaking Data: Super Responders With Delgocitinib for CHE
Late Breaking: Data From Pivotal Trial Reports Dupilumab Effective for Bullous Pemphigoid
Adewole Adamson, MD, MPP: Addressing Melanoma Diagnosis and Overdiagnosis